Cargando…

Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies

OBJECTIVE: Chimeric antigen receptor-modified T (CAR-T) cells have shown impressive results against relapsed/refractory B cell malignancies. However, the traditional manufacture of CAR-T cells requires leukapheresis to isolate large amounts of peripheral blood T cells, thus making some patients inel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Lu, Zhou, Jian, Li, Linlin, Zhou, Keshu, Zhao, Lingdi, Zhu, Xinghu, Yin, Qingsong, Li, Yufu, You, Hongqin, Zhang, Jishuai, Song, Yongping, Gao, Quanli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610157/ https://www.ncbi.nlm.nih.gov/pubmed/34390235 http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0040

Ejemplares similares

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
por: Han, Lu, et al.
Publicado: (2020)

Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph(+) B cell acute lymphoblastic leukemia
por: Han, Lu, et al.
Publicado: (2022)

The Application of Nanobody in CAR-T Therapy
por: Bao, Chaolemeng, et al.
Publicado: (2021)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
por: Ren, Quan, et al.
Publicado: (2023)

Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia
por: Zhou, Keshu, et al.
Publicado: (2017)

A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy
por: Huang, Zhenghua, et al.
Publicado: (2023)

Current state of CAR-T therapy for T-cell malignancies
por: Luo, Liangkui, et al.
Publicado: (2022)

Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma
por: Li, Zhen, et al.
Publicado: (2023)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma
por: Lin, Quande, et al.
Publicado: (2019)

Mesenchymal stem cells derived from human induced pluripotent stem cells retain adequate osteogenicity and chondrogenicity but less adipogenicity
por: Kang, Ran, et al.
Publicado: (2015)

Erratum to: CAR T Cell Therapy for Hematological Malignancies
por: Yang, Xin, et al.
Publicado: (2021)

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma
por: Li, Wei, et al.
Publicado: (2017)

Omacetaxine mepesuccinate induces apoptosis and cell cycle arrest, promotes cell differentiation, and reduces telomerase activity in diffuse large B-cell lymphoma cells
por: ZHANG, LINA, et al.
Publicado: (2016)

T cell senescence and CAR-T cell exhaustion in hematological malignancies
por: Kasakovski, Dimitri, et al.
Publicado: (2018)

Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19(+) malignancy
por: Pennell, Christopher A, et al.
Publicado: (2022)

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
por: Cheng, Jiali, et al.
Publicado: (2019)

Changes of T-lymphocyte subpopulation and differential expression pattern of the T-bet and GATA-3 genes in diffuse large B-cell lymphoma patients after chemotherapy
por: Yin, Qingsong, et al.
Publicado: (2014)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

T-cell immunoglobulin and mucin domain-containing protein-3 and galectin-9 protein expression: Potential prognostic significance in esophageal squamous cell carcinoma for Chinese patients
por: Hou, Nan, et al.
Publicado: (2017)

Pan-Cancer Analysis Identifies Tumor Cell Surface Targets for CAR-T Cell Therapies and Antibody Drug Conjugates
por: Li, Xinhui, et al.
Publicado: (2022)

LINC00963 facilitates acute myeloid leukemia development by modulating miR-608/MMP-15
por: Zuo, Wenli, et al.
Publicado: (2020)

In Vertebral Hemangiomas with Neurological Deficit, Is a Less Extensive Approach Adequate?
por: Guna Pratheep, K., et al.
Publicado: (2023)

The Application of CAR-T Cells in Haematological Malignancies
por: Skorka, Katarzyna, et al.
Publicado: (2020)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

Clinical trials of CAR-T cells in China
por: Liu, Bingshan, et al.
Publicado: (2017)

Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer
por: Zhao, Lingdi, et al.
Publicado: (2020)

Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
por: Hou, Jiangxue, et al.
Publicado: (2023)

KIAA0101 knockdown inhibits cell proliferation and induces cell cycle arrest and cell apoptosis in chronic lymphocytic leukemia cells
por: Zhang, Qing, et al.
Publicado: (2021)

Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials
por: Zhao, Lingdi, et al.
Publicado: (2015)

Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
por: Ding, Jing, et al.
Publicado: (2022)

Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
por: Hou, Jiangxue, et al.
Publicado: (2023)

Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
por: Li, Hongwen, et al.
Publicado: (2022)

On the Curability of Malignant Tumors of the Breast by Adequate Operations
por: Gross, Samuel W.
Publicado: (1881)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

CAR T Cell Immunotherapy Beyond Haematological Malignancy
por: Hupperetz, Cedric, et al.
Publicado: (2022)

Clinical characteristics and prognosis of 16 relapsed/refractory B-cell malignancy patients with CAR T-cell-related hyperferritinaemia
por: Zhou, Lanlan, et al.
Publicado: (2022)

Down‐regulated IL36RN expression based on peripheral blood mononuclear cells and plasma of periodontitis patients and its clinical significance
por: Zhou, Yue, et al.
Publicado: (2021)

CAR-T Cells Microscopic and Phenotypic Identification in the Peripheral Blood
por: Lesesve, Jean-François, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c6ij5194a7hfuekmhlm7finp01